CareDx/$CDNA
1D1W1MYTD1Y5YMAX
Capital at risk
About CareDx
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
- Ticker
- $CDNA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 763
- Headquarters
- Brisbane, United States
- Website
- caredx.com
CareDx Metrics
BasicAdvanced
$2.6B
23.73
$2.12
2.43
-
Price and volume
Market cap
$2.6B
Beta
2.43
52-week high
$53.67
52-week low
$13.12
Average daily volume
1.2M
Financial strength
Current ratio
4.581
Quick ratio
4.355
Long term debt to equity
3.102
Total debt to equity
4.522
Profitability
EBITDA (TTM)
12.433
Gross margin (TTM)
70.58%
Net profit margin (TTM)
24.23%
Operating margin (TTM)
-0.43%
Effective tax rate (TTM)
3.63%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
-0.25%
Return on equity (TTM)
29.49%
Valuation
Price to earnings (TTM)
23.729
Price to revenue (TTM)
5.662
Price to book
6.09
Price to tangible book (TTM)
6.98
Price to free cash flow (TTM)
30.865
Free cash flow yield (TTM)
3.24%
Free cash flow per share (TTM)
1.63
Growth
Revenue change (TTM)
34.41%
Earnings per share change (TTM)
112.54%
3-year revenue growth (CAGR)
13.99%
10-year revenue growth (CAGR)
30.86%
3-year earnings per share growth (CAGR)
10.51%
10-year earnings per share growth (CAGR)
-0.85%
What the Analysts think about CareDx
Analyst ratings (Buy, Hold, Sell) for CareDx stock.
Analyst projections of the future price of CareDx stock.
Bulls say / Bears say
Q2 2026 revenue grew 52% year-over-year to $132 million, driven by 61% growth in Testing Services and 50% growth in Patient and Digital Solutions, reflecting strong transplant program demand and favorable reimbursement dynamics. (SEC)
GAAP net income reached $111 million in Q2 2026 versus a $9 million loss in Q2 2025, and adjusted EBITDA rose to $25 million from $5 million, demonstrating improved profitability and operational leverage. (SEC)
Finalization of Medicare Local Coverage Determination for AlloSure and AlloMap led to a 20% share price surge, securing reimbursement clarity and supporting continued patient access to transplant molecular testing. (Investing.com)
Q2 2026 GAAP net income was largely driven by a one-time $113 million gain on the sale of the Lab Products business, with non-GAAP net income of $20 million indicating more modest core profitability. (SEC)
CDNA trades at a P/E of 22.7x and price/sales multiple of 5.5x, well above peer averages of 5.7x and sector averages of 3.1x, suggesting valuation may be stretched and vulnerable if growth decelerates. (Investing.com)
Key pipeline program AlloHeme remains in clinical development and CLIA readiness, exposing the company to regulatory and execution risk before it can materially diversify revenue beyond core testing services. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
CareDx Financial Performance
Revenues and expenses
CareDx Earnings Performance
Company profitability
Upcoming events
No upcoming events
CareDx News
AllArticlesVideos
Funds containing CareDx
AllUSDEURGBP
Fund name | Fund size | $CDNA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.19% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.19% |
iShares Healthcare Innovation£DRDR | £1B | 0.19% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.09% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.